Gerard Zanolli, MD
Psychiatry · Seattle, WANPI 1730274382
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 39.0% of the total. Reporting peaked in 2019 at $919 and has fallen 89.0% since, to $101 in 2025. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $28.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- AbbVie$503
- Johnson & Johnson$408
- Otsuka America Pharmaceutical, Inc.$294
- Jazz Pharmaceuticals Inc.$149
- Lundbeck LLC$106
- plus $327 from 7 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Food & beverage$2,86698%
- Education$612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 11 | $1,141 |
| AbbVie(2 entities) | 39 | $503 |
| Johnson & Johnson | 12 | $408 |
| Otsuka America Pharmaceutical, Inc. | 18 | $294 |
| Jazz Pharmaceuticals Inc. | 2 | $149 |
| Lundbeck LLC | 6 | $106 |
| Ironshore Pharmaceuticals Inc. | 3 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Sunovion Pharmaceuticals Inc. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Shire North American Group Inc | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,927 in reported general payments places this provider in the 90th percentile of 576 psychiatry providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 15 | $54,854 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 149 | $6,512 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 81 | $6,346 |
| Aripiprazole | 126 | $5,260 |
| Lamotrigine | 320 | $4,894 |
| Buspirone Hcl | 79 | $2,066 |
| Gabapentin | 87 | $1,934 |
| Quetiapine Fumarate | 113 | $1,909 |
| Lithium Carbonate ErLithium Carbonate | 123 | $1,872 |
| Olanzapine | 88 | $1,826 |
| Risperidone | 84 | $1,825 |
| Divalproex Sodium ErDivalproex Sodium | 35 | $1,675 |
| Ziprasidone Hcl | 11 | $1,658 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 15 | $1,646 |
| Duloxetine Hcl | 75 | $1,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $408 | $54,85415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 576 psychiatry providers in Washington.
Other psychiatry in Seattle
- Chester RobachinskiSeattle$1.1M
- Pablo ProanoSeattle$112K
- Jesse McClellandSeattle$39K
- Lina FineSeattle$30K
- Jonathan BuchholzSeattle$7K
- Steven MitchellSeattle$7K
- Randall EspinozaSeattle$6K
- John KernSeattle$6K
- James BowenSeattle$4K
- Shahm MartiniSeattle$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.